By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid today announced a partnership with Novartis to commercialize a molecular diagnostic test for Philadelphia chromosome-positive chronic myelogenous leukemia, or Ph+CML.

The Xpert BCR-ABL test is based on Cepheid's GeneXpert system. It is CE marked and has been available for sale outside the US since 2006. The deal announced today would accelerate efforts to get clearance from the US Food and Drug Administration for commercial launch in the US of the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.